AU2004283038B9 - Use of neurokinin antagonists in the treatment of urinary incontinence - Google Patents

Use of neurokinin antagonists in the treatment of urinary incontinence Download PDF

Info

Publication number
AU2004283038B9
AU2004283038B9 AU2004283038A AU2004283038A AU2004283038B9 AU 2004283038 B9 AU2004283038 B9 AU 2004283038B9 AU 2004283038 A AU2004283038 A AU 2004283038A AU 2004283038 A AU2004283038 A AU 2004283038A AU 2004283038 B9 AU2004283038 B9 AU 2004283038B9
Authority
AU
Australia
Prior art keywords
phenyl
hydrogen
alkyl
formula
azacycloheptan
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2004283038A
Other languages
English (en)
Other versions
AU2004283038B2 (en
AU2004283038A1 (en
Inventor
Paul William Glue
Kevin Hall Mcallister
Eckhard Weber
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis AG
Original Assignee
Novartis AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34520229&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AU2004283038(B9) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis AG filed Critical Novartis AG
Publication of AU2004283038A1 publication Critical patent/AU2004283038A1/en
Application granted granted Critical
Publication of AU2004283038B2 publication Critical patent/AU2004283038B2/en
Publication of AU2004283038B9 publication Critical patent/AU2004283038B9/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Urology & Nephrology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
AU2004283038A 2003-10-27 2004-10-26 Use of neurokinin antagonists in the treatment of urinary incontinence Ceased AU2004283038B9 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US51479103P 2003-10-27 2003-10-27
US60/514,791 2003-10-27
PCT/EP2004/012081 WO2005039563A2 (en) 2003-10-27 2004-10-26 Use of neurokinin antagonists in the treatment of urinary incontinence

Publications (3)

Publication Number Publication Date
AU2004283038A1 AU2004283038A1 (en) 2005-05-06
AU2004283038B2 AU2004283038B2 (en) 2008-01-31
AU2004283038B9 true AU2004283038B9 (en) 2008-04-24

Family

ID=34520229

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2004283038A Ceased AU2004283038B9 (en) 2003-10-27 2004-10-26 Use of neurokinin antagonists in the treatment of urinary incontinence

Country Status (9)

Country Link
US (1) US7776851B2 (enExample)
EP (2) EP1686985A2 (enExample)
JP (1) JP2007509184A (enExample)
CN (1) CN1874766A (enExample)
AU (1) AU2004283038B9 (enExample)
BR (1) BRPI0415923A (enExample)
CA (1) CA2543552A1 (enExample)
MX (1) MXPA06004688A (enExample)
WO (1) WO2005039563A2 (enExample)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1938804A1 (en) * 2006-12-22 2008-07-02 Novartis AG Pharmaceutical formulation comprising neurokinin antagonist

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998007694A1 (en) * 1996-08-22 1998-02-26 Novartis Ag Acylaminoalkenylene-amide derivatives as nk1 and nk2 antagonists
WO2003066062A1 (en) * 2002-02-08 2003-08-14 Novartis Ag Use of acylaminoalkenylene-amide derivatives in functional motility disorders of the viscera

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH06509087A (ja) * 1991-07-05 1994-10-13 メルク　シヤープ　エンド　ドーム　リミテツド 芳香族化合物、それらを含む医薬組成物、及び治療におけるそれらの使用
FR2700472B1 (fr) * 1993-01-19 1995-02-17 Rhone Poulenc Rorer Sa Association synergisante ayant un effet antagoniste des récepteurs NK1 et NK2.
GB0015246D0 (en) * 2000-06-22 2000-08-16 Astrazeneca Ab Method for the treatment of urinary incontinence
US6664253B2 (en) * 2000-10-17 2003-12-16 Boehringer Ingelheim Pharma Kg Neurokinin antagonists
CA2432543A1 (en) * 2000-12-22 2002-07-04 Takeda Chemical Industries, Ltd. Combination drugs
US7335776B2 (en) * 2001-03-14 2008-02-26 Ono Pharmaceutical Co., Ltd. Remedies for depression containing EP1 antagonist as the active ingredient
KR100887471B1 (ko) * 2002-01-18 2009-03-10 교린 세이야꾸 가부시키 가이샤 축합 바이사이클릭 피리미딘 유도체
US7026309B2 (en) * 2002-03-26 2006-04-11 Kyorin Pharmaceutical Co., Ltd. Fused bicyclic pyridine derivative as tachykinin receptor antagonist
CN1330654C (zh) * 2002-03-26 2007-08-08 杏林制药株式会社 稠合双环嘧啶衍生物

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998007694A1 (en) * 1996-08-22 1998-02-26 Novartis Ag Acylaminoalkenylene-amide derivatives as nk1 and nk2 antagonists
WO2003066062A1 (en) * 2002-02-08 2003-08-14 Novartis Ag Use of acylaminoalkenylene-amide derivatives in functional motility disorders of the viscera

Also Published As

Publication number Publication date
US20070149504A1 (en) 2007-06-28
JP2007509184A (ja) 2007-04-12
WO2005039563A3 (en) 2005-06-30
WO2005039563A2 (en) 2005-05-06
EP1686985A2 (en) 2006-08-09
US7776851B2 (en) 2010-08-17
AU2004283038B2 (en) 2008-01-31
BRPI0415923A (pt) 2006-12-26
CA2543552A1 (en) 2005-05-06
CN1874766A (zh) 2006-12-06
EP2158910A1 (en) 2010-03-03
MXPA06004688A (es) 2006-07-05
AU2004283038A1 (en) 2005-05-06

Similar Documents

Publication Publication Date Title
EP3129023B1 (en) Potent soluble epoxide hydrolase inhibitors
US20260102382A1 (en) Methods for treatment of fibrotic diseases
US6946474B2 (en) Nitrogen-containing compounds and their use as glycine transport inhibitors
US20120077818A1 (en) Compositions comprising transnorsertraline and serotonin receptor 1a agonists/antagonists and uses thereof
US20110124683A1 (en) Use of CRTH2 Antagonist Compounds
SK284923B6 (sk) Zmes liečiv s antidepresívnym účinkom obsahujúca 2-amino-4,5,6,7- tetrahydro-6-propylaminobenzotiazol a sertralín a jej použitie
KR20050057673A (ko) Ｊｎｋ 억제제를 이용한 통증의 치료
WO2005117872A2 (en) Dual acting snri-nmda antagonists for the treatment of genitourinary disorders
HRP20020117A2 (en) Use of cgrp antagonists and cgrp release inhibitors for combating menopausal hot flushes
US20240390399A1 (en) Materials and methods for suppressing and/or treating bone related diseases and symptoms
US20040235922A1 (en) Compositions and methods for inducing adipose tissue cell death
AU2004283038B2 (en) Use of neurokinin antagonists in the treatment of urinary incontinence
JPH10502656A (ja) ヒトｓ−ｃｄ２３の阻害剤の使用
JP2015516452A (ja) （１ｒ，４ｒ）−６’−フルオロ−Ｎ，Ｎ−ジメチル−４−フェニル−４’，９’−ジヒドロ−３’Ｈ−スピロ［シクロヘキサン−１，１’−ピラノ［３，４，ｂ］インドール］−４−アミンおよび抗けいれん剤を含む医薬組成物
US6011054A (en) Method for treating depression, obsessive compulsive disorder, and anxiety with N--acetyl serotonin
CN113613653A (zh) 治疗边缘型人格障碍的方法
US6335372B1 (en) Treatment of obsessive compulsive disorder
US20070293473A1 (en) Use of acylaminoalkenylene-amide derivatives in functional motility disorders of the viscera
SK278918B6 (sk) Farmaceutický prostriedok proti vysokému krvnému t
EP1937264B1 (en) Combination therapy for the treatment of urinary frequency, urinary urgency and urinary incontinence
WO2001085696A1 (en) Butenoic acids derivatives and their use in the treatment of rhinitis
HK1145139A (en) Use of acylaminoalkenylene-amide derivatives in irritable bowel syndrome and functional dyspepsia
SK13392001A3 (sk) Použitie zlúčeniny a farmaceutická kompozícia ju obsahujúca
JPS6241208B2 (enExample)
HUP0200500A2 (en) Use of n,n-dimethyl-1-[1-(4chlorophenyl)cyclobutyl]-3-methylbutylamine for aiding weight loss after pregnancy

Legal Events

Date Code Title Description
SREP Specification republished
FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired